Chemomab Therapeutics Ltd.
Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for fibro-inflammatory diseases with high unmet need. Their lead asset, nebokitug (CM-101), is a first-in-class monoclonal antibody targeting CCL24, a key driver of fibrosis and inflammation. Chemomab's research indicates nebokitug has the potential to interrupt the deleterious pathological processes of fibro-inflammatory diseases and has shown promising results in clinical trials.
Registre Officiel
Analyse Qualité IA
Détails du Score de Confiance
Liens Rapides
Points forts du site
🌟 Entreprises similaires de confiance
Context Therapeutics Inc.
Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.
AGENUS INC
Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.
Sigyn Therapeutics, Inc.
Sigyn Therapeutics develops dialysis-like therapies for cardiovascular disease and cancer. Their therapies are designed to improve patient quality of life. Key products include CardioDialysis™ for cardiovascular disease, and ImmunePrep™, ChemoPrep™ and ChemoPure™ for cancer therapy.